Medicare Covers Veracyte's Prosigna Breast Cancer Test, Opening U.S. Reimbursement
VCYT sits 54% above its 52-week low of $29.455.
Summary
Medicare's MolDX program will cover Veracyte's Prosigna Breast Risk of Recurrence test for postmenopausal ER+ stage I/II patients with 0-3 positive nodes, effective Aug. 19, 2026. The test launched in the U.S. in June, so reimbursement arrives quickly and removes the main barrier to adoption. Prosigna helps guide chemo-sparing decisions, which gives physicians and payers a clinical rationale to use it. This is a modest but real commercial milestone for a company that just posted $150.3M in quarterly revenue and $25.5M net profit, and it follows the September acquisition of Convergent Genomics that expanded the urology franchise. The next proof point is whether private payers follow Medicare and whether management discloses Prosigna revenue on the Q3 call.
At the time of this announcement, VCYT was trading at $45.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $29.46 to $60.91. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.